| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 06/13/2002 | WO2002045693A1 Pharmaceutical preparation comprising an active dispersed on a matrix |
| 06/13/2002 | WO2002045692A1 Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient |
| 06/13/2002 | WO2002045691A2 Laboratory scale milling process |
| 06/13/2002 | WO2002045690A1 Synthesis of small particles |
| 06/13/2002 | WO2002045689A1 Compositions for sustained delivery of hydrophobic drugs and process for the preparation thereof |
| 06/13/2002 | WO2002045688A2 Composition for treatment of inflammatory disorders |
| 06/13/2002 | WO2002045687A2 Topical alcoholic solution of a salicylic acid derivative and acemannan |
| 06/13/2002 | WO2002045686A2 Pharmaceutical paste comprising an acid-labile active ingredient |
| 06/13/2002 | WO2002045685A2 Cristallizable/non crystallizable polymer composites |
| 06/13/2002 | WO2002045684A2 Rapidly dispersing pharmaceutical composition comprising effervescent agents |
| 06/13/2002 | WO2002045683A2 Reversible gelling system for ocular drug delivery |
| 06/13/2002 | WO2002045682A1 Particulate inhalation carrier |
| 06/13/2002 | WO2002045681A2 Solid polyunsaturated fatty acid compositions |
| 06/13/2002 | WO2002045618A2 Oral capsule for administering tablets to animals |
| 06/13/2002 | WO2002045575A2 Multicomponent biodegradable bioadhesive controlled release system for oral care products |
| 06/13/2002 | WO2002045573A2 Condom with male genital desensitizer lubricant |
| 06/13/2002 | WO2002045571A2 Fast dissolving tablet |
| 06/13/2002 | WO2002038530A8 Carboxylic acid type lipid |
| 06/13/2002 | WO2002022204A3 Transdermal electrotransport device and method for manufacturing same |
| 06/13/2002 | WO2002022156A3 Topical formulations for delivery of interleukin-11 |
| 06/13/2002 | WO2002020554A3 Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines |
| 06/13/2002 | WO2002017857A3 Methods and compositions for inhibiting angiogenesis |
| 06/13/2002 | WO2002016442A3 Microparticle composition and method |
| 06/13/2002 | WO2002009710A3 Paroxetine tablets and capsules |
| 06/13/2002 | WO2002007712A3 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs |
| 06/13/2002 | WO2002003998A3 Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
| 06/13/2002 | WO2002003962A3 Drug delivery system for poorly water soluble drugs |
| 06/13/2002 | WO2002000173A3 Methods for use of delivery composition for expanding, activating, committing or mobilizing one or more pluripotent, self-renewing and committed stem cells |
| 06/13/2002 | WO2001098297A3 A thiazine oxazolidinone |
| 06/13/2002 | WO2001095884A3 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| 06/13/2002 | WO2001094547A3 Molecular delivery vehicle for delivery of selected compounds to targets |
| 06/13/2002 | WO2001093829A3 Powder compositions |
| 06/13/2002 | WO2001089554A3 Treatment of acute coronary syndrome with glp-1 |
| 06/13/2002 | WO2001085257A3 Opioid antagonist compositions and dosage forms |
| 06/13/2002 | WO2001082899A3 Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites |
| 06/13/2002 | WO2001074839A3 Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha, 11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use |
| 06/13/2002 | WO2001072277A3 Immunotherapeutic methods and compositions |
| 06/13/2002 | WO2001035942A3 Analgesic compositions containing buprenorphine |
| 06/13/2002 | WO2001028538A3 Laxative preparation containing l-arginine |
| 06/13/2002 | WO2000057838A3 Coating system |
| 06/13/2002 | US20020073428 Downloading and transfer of audio or video data from video broadcasts |
| 06/13/2002 | US20020072784 Microchip reservoir devices using wireless transmission of power and data |
| 06/13/2002 | US20020072735 Multi-step drug dosage forms |
| 06/13/2002 | US20020072734 Chip systems for the controlled emission of substances having a chemosensory effect |
| 06/13/2002 | US20020072733 Devices, systems and methods for patient infusion |
| 06/13/2002 | US20020072540 For therapy, prophylaxis and diagnosis of respiratory distress syndrome or other pulmonary diseases that are associated with deficiency of lung surfactant |
| 06/13/2002 | US20020072498 Method for administering ciliary neurotrophic factor to the brain |
| 06/13/2002 | US20020072480 Water-soluble, chlorhexidine-containing compositions and use thereof |
| 06/13/2002 | US20020072121 Composition for use in stable transfer on nucleotide sequences into cells |
| 06/13/2002 | US20020071908 Storage-stable particle, in particular carrier for carrier-bound reactions, and methods of producing said particle |
| 06/13/2002 | US20020071902 Applying a polymer in solvent mixture with finely divided bioactive species such as heparin, and curing, where the particle size of the bioactive species is selected to affect delivery kinetics |
| 06/13/2002 | US20020071874 Compositions containing therapeutically active components having enhanced solubility |
| 06/13/2002 | US20020071872 Laxative composition |
| 06/13/2002 | US20020071871 Produce substantially monodisperse particles or multimodal particles having well defined and controllable particle size distributions for pulmonary administration; spray drying |
| 06/13/2002 | US20020071870 Particulates of a water-insoluble pharmaceutical having a solubility of less than 15 mg/ml in an aqueous carrier liquid, then microfluidizing said composition in the presence of at least 0.01% by weight of particulates of a dextrin. |
| 06/13/2002 | US20020071869 Microparticle composition and method |
| 06/13/2002 | US20020071868 Compound that enhances the bioavailability of biological agents, compound that enhances intracellular signaling processes, and compound that enhances cell proliferation and cell survival. |
| 06/13/2002 | US20020071866 Controlling the depth of laser ablation of a dosage form during laser formation of an exit orifice in an outer wall of the dosage form. |
| 06/13/2002 | US20020071865 Quick disintegrating tablet in buccal cavity and manufacturing method thereof |
| 06/13/2002 | US20020071864 Rapidly disintegrable tablet for oral administration |
| 06/13/2002 | US20020071863 Sustained release oral dosage form that is free of in-situ aggregation effect of the antiviral drug and provides substantially improved bioavailability of said antiviral drug. |
| 06/13/2002 | US20020071862 Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis, and pharmaceutical compositions, and kit related thereto |
| 06/13/2002 | US20020071861 System for dermal or transdermal application containing an iota-carrageenan and process for its preparation |
| 06/13/2002 | US20020071860 Intraoral adhesive preparation |
| 06/13/2002 | US20020071857 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
| 06/13/2002 | US20020071852 Products for topical applications comprising oil bodies |
| 06/13/2002 | US20020071846 Vaccines comprising oil bodies |
| 06/13/2002 | US20020071843 Targeted therapeutic agents |
| 06/13/2002 | US20020071837 Preferred hyaluronidase enzyme is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,OOO MW |
| 06/13/2002 | US20020071835 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
| 06/13/2002 | US20020071815 Antipsoriatic nail polish |
| 06/13/2002 | US20020071812 Contain 1,1,1,2,3,3,3-heptafluoropropane; especially with a betamimetic, an anticholinergic, a steroid, an antiallergic or a PAF-antagonist or a combination of such compounds. |
| 06/13/2002 | US20020071810 Container is provided with a non-metal interior surface so as to reduce chemical degradation |
| 06/13/2002 | US20020071809 Effervescence as a penetration enhancer for drugs known, or suspected, of having poor bioavailability. |
| 06/13/2002 | DE19958554C2 Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung Microreservoir system based on polysiloxanes and ambiphilic solvents and their preparation |
| 06/13/2002 | DE10061057A1 Chip-Systeme zur kontrollierten Emission chemosensorisch wirkender Stoffe Chip systems for the controlled emission chemosensory of active substances |
| 06/13/2002 | DE10059822A1 Saure kosmetische, pharmazeutische und dermatologische Mittel Acid cosmetic, pharmaceutical and dermatological compositions |
| 06/13/2002 | DE10059821A1 Tensidfreie kosmetische, dermatologische und pharmazeutische Mittel Surfactant-free cosmetic, dermatological and pharmaceutical agents |
| 06/13/2002 | DE10059213A1 Preparing solid composition of poorly soluble compounds, useful e.g. for carotenoid animal feed additives, by flocculating a dispersion with protective colloid |
| 06/13/2002 | DE10059151A1 Magnetische Partikel zur Zielgerichteten Regionalen Therapie Magnetic particles for Targeted Therapy Regional |
| 06/13/2002 | DE10049137A1 Production of oily suspensions of water soluble vitamins comprises milling of vitamins in oil or dry milling and suspension in oil |
| 06/13/2002 | CA2436692A1 Oral extended release formulation of gepirone |
| 06/13/2002 | CA2436574A1 Laboratory scale milling process |
| 06/13/2002 | CA2436570A1 Rapidly dispersing pharmaceutical composition comprising effervescent agents |
| 06/13/2002 | CA2432549A1 Clear propofol compositions |
| 06/13/2002 | CA2431179A1 Synthesis of small particles |
| 06/13/2002 | CA2430874A1 Absorbing agents and cover layer which is impermeable to active substances and which contains channel-formers or removable protective layer of a transdermal therapeutic system |
| 06/13/2002 | CA2429727A1 Solid polyunsaturated fatty acid compositions |
| 06/13/2002 | CA2426988A1 Multicomponent compositions containing chitosan and methods of preparing same |
| 06/12/2002 | EP1213351A2 Nucleic acid enzymes acquiring an activity for cleaving a target RNA by recognising another molecule |
| 06/12/2002 | EP1213032A1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| 06/12/2002 | EP1213020A2 Pharmaceutical compositions having appetite suppressant activity |
| 06/12/2002 | EP1213018A1 Preventive and therapeutic agents for eye diseases |
| 06/12/2002 | EP1213016A2 Chip systems for controlled emission of chemosensorically active agents |
| 06/12/2002 | EP1213015A1 Oral pharmaceutical composition with delayed release of proton pump inhibitors |
| 06/12/2002 | EP1213014A2 Process and system for controlled-release drug delivery |
| 06/12/2002 | EP1213013A2 Process for preparing solid compositions of water-soluble, hardly water-soluble or water-insoluble active agents |
| 06/12/2002 | EP1213012A2 Improvements in and relating to powders for use in dry powder inhalers |
| 06/12/2002 | EP1212601A1 Glucose biosensor |
| 06/12/2002 | EP1212349A1 Recombinant subunit vaccine |